

Special Issue

Hypouricemia

Message from the Guest Editors

Hypouricemia was regarded as an interesting disorder in that it provided valuable information about the role of uric acid in the body. In recent years, the clinical importance of hypouricemia has increased, as hypouricemia has been found to have several complications. Remarkable advances in urate transporter studies and studies related with enzymes in metabolic pathways to uric acid have facilitated the elucidation of the pathogenesis of hypouricemia. This Special Issue of *Biomedicines* focuses on recent advances in the field of primary hypouricemia associated with decreased urate production and/or increased urate clearance concerning the molecular mechanism, as well as the clinical implication and implementation. The goal is to stimulate research and clinical interest in this exciting field with the hope of improving our understanding of urate handling and urate-related influence. Expanding our knowledge of the rare condition, hypouricemia, will allow us to better understand the pathogenetic mechanism of common hyperuricemia and gout, including the potential identification of new diagnostic and therapeutic strategies.

Guest Editors

Dr. Blanka Stiburkova

Institute of Rheumatology, Prague, Czech Republic and Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic

Prof. Dr. Kimiyoshi Ichida

Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan and Division of Kidney and Hypertension, Jikei University School of Medicine, Tokyo, Japan

Deadline for manuscript submissions

closed (31 May 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/69670

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).